Timing note: Today is Wednesday, August 5, 2026. The available pre-earnings market digest identifies KHC’s 2Q26 release as scheduled before the U.S. market open on August 5, not “tomorrow.” This preview is therefore framed for the results and ensuing management Q&A today.
KHC’s second-quarter report is less about whether reported revenue and EPS decline—both are expected to decline sharply—and more about whether management can demonstrate that the turnaround is gaining traction beneath a deliberately difficult near-term P&L.
The central investment debate is straightforward:
The setup is no longer as washed out as it was earlier in the year. KHC closed at $26.66 on August 4, up roughly 16% since its May 6 first-quarter report and about 9% year to date. That recovery raises the importance of credible execution evidence rather than simply a headline beat against lowered estimates.
The pre-report consensus framing is for:
| Metric | 2Q26 expectation | Year-over-year change |
|---|---|---|
| Organic net sales | (3.5%) | — |
| Volume/mix | (4.1%) | — |
| Adjusted EBITDA | $1.28 billion | (16%) |
| Adjusted EPS | $0.53 | (23%) |
For context, 2Q25 organic sales fell 2.0%, volume/mix declined 2.7%, adjusted operating income was $1.276 billion, and adjusted EPS was $0.69. Thus, consensus anticipates a materially worse year-over-year organic-sales and earnings comparison in 2Q26.
Management explicitly prepared investors for a weak second quarter at the 1Q call, guiding to organic-sales growth of negative 3% to negative 5%. Three factors matter:
Easter timing reversal.
KHC said 1Q benefited from the Easter shift and some weather-related pantry loading. Those benefits reverse in 2Q, making the quarterly comparison mechanically tougher.
SNAP headwind.
Management expects approximately 100 basis points of full-year organic-sales pressure from incremental SNAP headwinds, beginning in the second quarter. It said SNAP transaction softness was already visible in February and March, though stronger non-SNAP household demand partly offset that pressure in 1Q.
Underlying category softness and volume pressure.
In 1Q26, KHC organic sales fell 0.4%, entirely because volume/mix declined 1.2%, partly offset by 0.8% pricing. North America organic sales fell 1.1%, with volume/mix down 1.5%. The 2Q question is whether the expected calendar and SNAP pressures are masking stabilization—or whether the volume problem is worsening.
For investors, the most important disclosures may be market-share and volume trends rather than reported sales.
Management characterized 1Q as an early proof point for its investment plan:
Those figures need confirmation in 2Q. A healthy result would be:
Conversely, a broad deterioration in share or an acceleration in North American volume declines would be concerning. KHC’s 2025 problem was not simply insufficient pricing—it was sustained volume loss, particularly in categories such as coffee, cold cuts, frozen foods, and certain condiments.
The consensus EBITDA decline of roughly 16% reflects a quarter where KHC is intentionally prioritizing commercial reinvestment and faces cost pressure.
KHC’s 1Q adjusted gross margin fell just 30 basis points to 34.1%, but management said approximately 40–50 basis points of benefits were nonrecurring. These included certain byproduct sales, factory-maintenance timing, and somewhat better-than-anticipated cheese costs.
That means a normalizing margin performance in 2Q should not automatically be interpreted as a fundamental disappointment.
Investors should focus on:
KHC reiterated its full-year outlook in May despite a better-than-expected 1Q. Whether it does so again will likely matter more than a small 2Q EPS beat or miss.
| Metric | Company outlook |
|---|---|
| Organic net sales | (1.5%) to (3.5%) |
| Constant-currency adjusted operating income | (14%) to (18%) |
| Adjusted gross margin | (25) to (75) bps |
| Adjusted EPS | $1.98–$2.10 |
| Free-cash-flow conversion | ~100% |
Management’s prior second-half framework relies on lapping Indonesia-related disruption, better U.S. share performance as investments ramp, strength behind Heinz in Europe, and improvement in Away From Home and emerging markets.
KHC announced a $600 million incremental investment program across marketing, sales, R&D, product superiority, and selected pricing actions. At the 1Q call, management said much of the spending was still to be deployed.
Investors should look for concrete evidence that investment is translating to distribution, velocity, and repeat purchases—not simply higher advertising expense.
Relevant launches and initiatives include:
KHC has emphasized simplifying the North American operating model and increasing commercial accountability. The U.S. business remains the key swing factor: North America represents the majority of sales and was down 1.1% organically in 1Q despite favorable Easter timing.
Management paused work on the previously contemplated corporate separation in February, arguing that resources should be focused on restoring profitable growth. Investors should listen for whether this remains simply a pause, whether portfolio actions are being considered separately, and whether the company sees any asset divestiture opportunities. But this should be secondary to the operating turnaround; a renewed focus on financial engineering before improved execution would likely be poorly received.
KHC enters the report with meaningful cash-generation capacity despite declining earnings.
In 1Q26:
Management attributed part of the strength to working-capital timing, inventory optimization, supplier-payment terms, and commodity-derivative collateral. It also cautioned that cash flow could decline in the second half as investment accelerates.
The balance-sheet watch item is debt repayment. KHC had nearly $1.9 billion of current maturities at the end of 1Q and said it expected to repay debt maturing in 2Q, while considering early repayment of a portion of the following year’s maturities. Confirmation of deleveraging would be constructive, but it is unlikely to outweigh a disappointing commercial outcome.
A constructive 2Q result would likely include:
The most concerning combination would be:
KHC is a prove-it turnaround rather than a clean earnings-recovery story. The market is already expecting a difficult 2Q, so a modest EPS shortfall may be less important than whether management can validate improving U.S. share, better innovation execution, and a credible path to second-half stabilization.
The near-term hurdle is low on absolute earnings but rising on execution credibility. A report that confirms the expected 2Q trough while preserving the full-year roadmap could extend the stock’s recovery. A report showing that volume weakness is structural—or that commercial spending is failing to generate traction—would likely reopen the downside debate.